Analysts expect that Autolus Therapeutics plc (NASDAQ:AUTL) will post sales of $500,000.00 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Autolus Therapeutics’ earnings, with the lowest sales estimate coming in at $300,000.00 and the highest estimate coming in at $820,000.00. Autolus Therapeutics posted sales of $340,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 47.1%. The business is scheduled to report its next earnings report on Thursday, May 6th.
On average, analysts expect that Autolus Therapeutics will report full year sales of $1.90 million for the current year, with estimates ranging from $1.00 million to $3.16 million. For the next financial year, analysts forecast that the firm will post sales of $7.56 million, with estimates ranging from $6.90 million to $8.21 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Autolus Therapeutics.
Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Wednesday, March 3rd. The company reported ($0.83) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.06). Autolus Therapeutics had a negative net margin of 8,652.90% and a negative return on equity of 54.01%. The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.43 million.
Several institutional investors and hedge funds have recently modified their holdings of AUTL. California Public Employees Retirement System increased its holdings in shares of Autolus Therapeutics by 3.2% in the 3rd quarter. California Public Employees Retirement System now owns 41,500 shares of the company’s stock valued at $483,000 after purchasing an additional 1,300 shares during the period. State Street Corp increased its holdings in Autolus Therapeutics by 115.4% in the third quarter. State Street Corp now owns 24,267 shares of the company’s stock worth $282,000 after buying an additional 12,999 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Autolus Therapeutics by 26.9% in the third quarter. JPMorgan Chase & Co. now owns 178,634 shares of the company’s stock worth $2,144,000 after buying an additional 37,879 shares during the last quarter. Pendal Group Limited acquired a new position in Autolus Therapeutics in the fourth quarter worth approximately $450,000. Finally, Wells Fargo & Company MN increased its holdings in Autolus Therapeutics by 62.4% in the fourth quarter. Wells Fargo & Company MN now owns 26,775 shares of the company’s stock worth $239,000 after buying an additional 10,292 shares during the last quarter. Institutional investors own 22.86% of the company’s stock.
AUTL stock traded down $0.25 during mid-day trading on Friday, reaching $5.29. 420,696 shares of the stock traded hands, compared to its average volume of 771,594. Autolus Therapeutics has a 52-week low of $5.10 and a 52-week high of $17.19. The company has a market cap of $276.91 million, a P/E ratio of -1.84 and a beta of 1.75. The stock’s fifty day moving average is $6.19 and its 200-day moving average is $8.84.
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.